{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:55:35Z","timestamp":1790445335305,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["189699"],"award-info":[{"award-number":["189699"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013348","name":"Innosuisse Swiss Innovation Agency","doi-asserted-by":"publisher","award":["54225.1 IP-LS"],"award-info":[{"award-number":["54225.1 IP-LS"]}],"id":[{"id":"10.13039\/501100013348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tranon.2026.102698","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T01:44:48Z","timestamp":1770947088000},"page":"102698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Imaging\u2013guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-8828","authenticated-orcid":false,"given":"Tommaso","family":"Virgilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Guixeras","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Pulfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6592-4253","authenticated-orcid":false,"given":"Chiara","family":"Pizzichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Latino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-0994","authenticated-orcid":false,"given":"Daniel","family":"Molina-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Capucetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Luca","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-7370","authenticated-orcid":false,"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Puca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4166-7664","authenticated-orcid":false,"given":"Santiago F.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102698_bib0001","unstructured":"Owen J.A., Punt J., Stranford S.A. Kuby Immunology 7th Ed. 2013. Accessed May 26, 2025. https:\/\/archive.org\/details\/OwenKubyImmunology7thEd.2013."},{"issue":"11","key":"10.1016\/j.tranon.2026.102698_bib0002","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.2022015849","article-title":"Developing a classification of hematologic neoplasms in the era of precision medicine","volume":"140","author":"Cazzola","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102698_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1409627","article-title":"Biomarkers of lymph node metastasis in colorectal cancer: update","volume":"14","author":"Zhu","year":"2024","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102698_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/modpathol.2012.92","article-title":"The clinical significance of lymph node size in colon cancer","volume":"25","author":"M\u00e4rkl","year":"2012","journal-title":"Modern Pathol"},{"key":"10.1016\/j.tranon.2026.102698_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081917","article-title":"Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond Rituximab","volume":"14","author":"Papageorgiou","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"6","key":"10.1016\/j.tranon.2026.102698_bib0007","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.102698_bib0008","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102698_bib0009","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ijc.2910590507","article-title":"The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis","volume":"59","author":"Castellani","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.tranon.2026.102698_bib0010","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","article-title":"Expression of the oncofetal ED-B\u2013containing fibronectin isoform in hematologic tumors enables ED-B\u2013targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients","volume":"113","author":"Sauer","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0011","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V94.1.192.413k22_192_198","article-title":"A high-affinity human antibody that targets tumoral blood vessels","volume":"94","author":"Tarli","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2026.102698_bib0012","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.tranon.2026.102698_bib0013","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.tranon.2026.102698_bib0014","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2003-04-1039","article-title":"Selective targeted delivery of TNFalpha to tumor blood vessels","volume":"102","author":"Borsi","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ejca.2011.02.001","article-title":"Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies","volume":"47","author":"Czabanka","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102698_bib0017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.111.101006","article-title":"Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies","volume":"53","author":"Erba","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102698_bib0018","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2013.421","article-title":"The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity","volume":"109","author":"Hemmerle","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.102698_bib0019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2326-6066.CIR-13-0007","article-title":"Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study","volume":"1","author":"Poli","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.102698_bib0020","first-page":"571","article-title":"Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer","volume":"9","author":"Santimaria","year":"2003","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0021","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","article-title":"Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study","volume":"64","author":"Danielli","year":"2015","journal-title":"Cancer Immunol., Immunother"},{"issue":"9","key":"10.1016\/j.tranon.2026.102698_bib0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","article-title":"A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients","volume":"68","author":"Weide","year":"2019","journal-title":"Cancer Immunol. Immunther."},{"issue":"3","key":"10.1016\/j.tranon.2026.102698_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00432-012-1327-7","article-title":"Phase I\/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours","volume":"139","author":"Spitaleri","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102698_bib0024","unstructured":"NidlegyTM Phase III PIVOTAL trial meets the study\u2019s primary. Accessed January 22, 2024. https:\/\/www.globenewswire.com\/news-release\/2023\/10\/16\/2760644\/0\/en\/Nidlegy-Phase-III-PIVOTAL-trial-meets-the-study-s-primary-objective-demonstrating-statistically-significant-and-clinically-meaningful-improvement-in-Recurrence-Free-Survival-for-pa.html."},{"issue":"11","key":"10.1016\/j.tranon.2026.102698_bib0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.7150\/thno.4652","article-title":"Image guided biodistribution and pharmacokinetic studies of theranostics","volume":"2","author":"Ding","year":"2012","journal-title":"Theranostics."},{"key":"10.1016\/j.tranon.2026.102698_bib0026","first-page":"203","article-title":"Cellular and molecular imaging of CAR-T cell-based immunotherapy","author":"Liu","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.tranon.2026.102698_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.semnuclmed.2008.02.001","article-title":"Pet\/mri: the next generation of multi-modality imaging?","volume":"38","author":"Pichler","year":"2008","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tranon.2026.102698_bib0028","doi-asserted-by":"crossref","unstructured":"Tansi F.L., R\u00fcger R., Kollmeier A.M., et al. A fast and effective determination of the biodistribution and subcellular localization of fluorescent immunoliposomes in freshly excised animal organs. 2017;17(1):1\u201311.","DOI":"10.1186\/s12896-017-0327-8"},{"issue":"50","key":"10.1016\/j.tranon.2026.102698_bib0029","doi-asserted-by":"crossref","first-page":"32005","DOI":"10.1073\/pnas.2015343117","article-title":"Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells","volume":"117","author":"Eisinger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.tranon.2026.102698_bib0030","doi-asserted-by":"crossref","unstructured":"Boulch M., Cazaux M., Loe-Mie Y., et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. 2021;6(57).","DOI":"10.1126\/sciimmunol.abd4344"},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0031","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/imr.13032","article-title":"Diving into the mechanism of action of tumor immunotherapies with intravital imaging*","volume":"306","author":"Bousso","year":"2022","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (l19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2026.102698_bib0033","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2967\/jnumed.107.040477","article-title":"Small-animal PET of tumor angiogenesis using a 76Br-labeled Human recombinant antibody fragment to the ED-B domain of fibronectin","volume":"48","author":"Rossin","year":"2007","journal-title":"J. Nuclear Med"},{"issue":"12","key":"10.1016\/j.tranon.2026.102698_bib0034","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/sj.bjc.6603806","article-title":"Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models","volume":"96","author":"El-Emir","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0035","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00259-009-1096-y","article-title":"124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy","volume":"36","author":"Tijink","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"issue":"9","key":"10.1016\/j.tranon.2026.102698_bib0036","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00262-014-1562-7","article-title":"Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy","volume":"63","author":"Pretto","year":"2014","journal-title":"Cancer Immunol., Immunother."},{"issue":"41","key":"10.1016\/j.tranon.2026.102698_bib0037","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.18632\/oncotarget.27726","article-title":"A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo","volume":"11","author":"Ongaro","year":"2020","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102698_bib0038","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jconrel.2019.11.036","article-title":"Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice","volume":"317","author":"Puca","year":"2020","journal-title":"J. Controll. Rel."},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13046-024-03238-x","article-title":"Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice","volume":"44","author":"Carbone","year":"2025","journal-title":"J. Experim. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2026.102698_bib0042","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/1878-0261.12705","article-title":"Human fibronectin extra domain B as a biomarker for targeted therapy in cancer","volume":"14","author":"Lieverse","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2026.102698_bib0043","doi-asserted-by":"crossref","unstructured":"Wang L., Rao Y., Liu X., et al. Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. 2021;19(1):56.","DOI":"10.1186\/s12951-021-00803-w"},{"key":"10.1016\/j.tranon.2026.102698_bib0044","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.omtm.2023.05.008","article-title":"Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution","volume":"29","author":"M\u00fcnter","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.tranon.2026.102698_bib0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nature Rev. Bioeng."},{"issue":"3","key":"10.1016\/j.tranon.2026.102698_bib0046","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0047","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity."},{"issue":"4","key":"10.1016\/j.tranon.2026.102698_bib0048","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41418-023-01117-0","article-title":"Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs","volume":"30","author":"Diepstraten","year":"2023","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.tranon.2026.102698_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152035","article-title":"Late-stage MC38 tumours recapitulate features of human colorectal cancer \u2013 implications for appropriate timepoint selection in preclinical studies","volume":"14","author":"Shields","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/pharmaceutics16080974","article-title":"Stimulating the antitumor immune response using immunocytokines: a preclinical and clinical overview","volume":"16","author":"Boersma","year":"2024","journal-title":"Pharmaceutics."},{"issue":"16","key":"10.1016\/j.tranon.2026.102698_bib0051","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase i clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2026.102698_bib0052","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00262-014-1562-7","article-title":"Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy","volume":"63","author":"Pretto","year":"2014","journal-title":"Cancer Immunol. Immunther."},{"issue":"4","key":"10.1016\/j.tranon.2026.102698_bib0053","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2326-6066.CIR-18-0566","article-title":"Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8+ T cells","volume":"7","author":"Hutmacher","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.102698_bib0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ni.2262","article-title":"Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks","volume":"13","author":"Malhotra","year":"2012","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0056","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s44222-023-00063-3","article-title":"Human disease models in drug development","volume":"1","author":"Loewa","year":"2023","journal-title":"Nature Rev. Bioeng."},{"issue":"11","key":"10.1016\/j.tranon.2026.102698_bib0057","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106658","article-title":"Functional heterogeneity of cytotoxic T cells and tumor resistance to cytotoxic hits limit anti-tumor activity in vivo","volume":"40","author":"Khazen","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.tranon.2026.102698_bib0058","doi-asserted-by":"crossref","unstructured":"Cazaux M., Grandjean C.L., Lema\u02c6\u0131treLema\u02c6\u0131tre F., et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. Published online 2019. doi:10.1084\/jem.20182375.","DOI":"10.1084\/jem.20182375"},{"issue":"12","key":"10.1016\/j.tranon.2026.102698_bib0059","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/2326-6066.CIR-22-0225","article-title":"Subcapsular sinus macrophages promote melanoma metastasis to the sentinel lymph nodes via an IL1\u03b1-STAT3 axis","volume":"10","author":"Virgilio","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tranon.2026.102698_bib0060","first-page":"650","article-title":"Targeting lymph node sinus macrophages to inhibit lymph node metastasis","volume":"16","author":"Hu","year":"2019","journal-title":"Molecular Ther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ame2.12102","article-title":"The role of mouse models in colorectal cancer research\u2014The need and the importance of the orthotopic models","volume":"3","author":"Oliveira","year":"2020","journal-title":"Animal. Model. Exp. Med."},{"key":"10.1016\/j.tranon.2026.102698_bib0062","first-page":"12","volume":"139","author":"Stein","year":"2017"},{"issue":"5\u20136","key":"10.1016\/j.tranon.2026.102698_bib0063","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/1061186X.2018.1561886","article-title":"Engineering polymeric nanocapsules for an efficient drainage and biodistribution in the lymphatic system","volume":"27","author":"Cordeiro","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.tranon.2026.102698_bib0064","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jconrel.2024.08.018","article-title":"Stealth mRNA nanovaccines to control lymph node trafficking","volume":"374","author":"Garc\u00eda-Fern\u00e1ndez","year":"2024","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.tranon.2026.102698_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114528","article-title":"Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes","volume":"189","author":"Momoh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tranon.2026.102698_bib0066","first-page":"1","article-title":"Whole-body cellular mapping in mouse using standard IgG antibodies","author":"Mai","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tranon.2026.102698_bib0067","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-981-15-7627-0_7","article-title":"Label-Free Multimodal Multiphoton Intravital Imaging","volume":"3233","author":"Park","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102698_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nano10112239","article-title":"Label-free visualization and tracking of gold nanoparticles in vasculature using multiphoton luminescence","volume":"10","author":"Burkitt","year":"2020","journal-title":"Nanomaterials. (Basel)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-31401-5","article-title":"Label-free multiphoton microscopy enables histopathological assessment of colorectal liver metastases and supports automated classification of neoplastic tissue","volume":"13","author":"Galli","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102698_bib0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-bioeng-112315-031200","article-title":"The lymphatic system in disease processes and cancer progression","volume":"18","author":"Padera","year":"2016","journal-title":"Annu Rev. Biomed. Eng."},{"key":"10.1016\/j.tranon.2026.102698_bib0071","doi-asserted-by":"crossref","unstructured":"Anderson P.M., Sorenson M.A. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. 1994;27(1):19\u201322.","DOI":"10.2165\/00003088-199427010-00003"},{"issue":"6","key":"10.1016\/j.tranon.2026.102698_bib0072","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/pharmaceutics15061664","article-title":"Anatomical targeting of anticancer drugs to solid tumors using specific administration routes: review","volume":"15","author":"Saito","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.tranon.2026.102698_bib0073","first-page":"1","article-title":"Same yet different \u2014 How lymph node heterogeneity affects immune responses","author":"Cruz de Casas","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102698_bib0074","article-title":"Lymphatic endothelial cells of the lymph node","author":"Jalkanen","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102698_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17291-5","article-title":"A molecular map of murine lymph node blood vascular endothelium at single cell resolution","author":"Brulois","year":"2020","journal-title":"Nature communications"},{"issue":"7095","key":"10.1016\/j.tranon.2026.102698_bib0076","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","article-title":"Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells","volume":"441","author":"Williams","year":"2006","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.tranon.2026.102698_bib0077","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102698_bib0078","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/jid.2012.376","article-title":"The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF","volume":"133","author":"Schwager","year":"2013","journal-title":"J. Investigat. Dermatol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0079","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.tranon.2026.102698_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir. Res."},{"issue":"9","key":"10.1016\/j.tranon.2026.102698_bib0081","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/ijc.32603","article-title":"The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors","volume":"146","author":"Puca","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"564","key":"10.1016\/j.tranon.2026.102698_bib0082","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102698_bib0083","article-title":"An antibody targeting fibroblast activation protein simultaneously fused to interleukin-2 and tumor necrosis factor selectively localizes to neoplastic lesions","volume":"12","author":"Prodi","year":"2023","journal-title":"Antibodies (Basel)"},{"issue":"8","key":"10.1016\/j.tranon.2026.102698_bib0084","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/j.1460-2075.1987.tb02509.x","article-title":"Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon","volume":"6","author":"Zardi","year":"1987","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.tranon.2026.102698_bib0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:00Z","timestamp":1781509560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":81,"alternative-id":["S1936523326000355"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102698","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging\u2013guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102698"}}